Type 1 procollagen as a biochemical marker of growth in children with inflammatory bowel disease |
| |
| Authors: | J S Hyams D E Carey A M Leichtner B D Goldberg |
| |
| Affiliation: | 1. Department of Pediatrics, Hartford Hospital, Hartford, Connecticut, USA;2. Department of Pediatrics, The University of Connecticut Health Center, Farmington, USA;3. Department of Pediatrics, Newington Children''s Hospital, Newington, Connecticut, USA;4. Department of Pathology, University of Wisconsin, Madison, USA;1. Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China;2. Department of Pathology, Affiliated Hospital of Weifang Medical University, Weifang, China;3. Branch of Shandong Provincial Clinical Research Center for Diabetes and Metabolic Diseases, and Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China;1. Engineering Research Centre of Fujian-Taiwan Special Marine Food Processing and Nutrition, Ministry of Education, Fuzhou 350002, China;2. College of Food Science, Fujian Agriculture and Forestry University, Fuzhou 350002, China;3. Key Laboratory of Marine Biotechnology of Fujian Province, Institute of Oceanology, Fujian Agriculture and Forestry University, Fuzhou 350002, China;4. College of Food Science and Nutritional Engineering, China Agricultural University, Beijing 100083, China |
| |
| Abstract: | ![]()
Using radioimmunoassay, we measured the levels of the C-terminal propeptide of type I procollagen (pColl-I-C) in sera from 69 children with functional bowel disease (control population), 18 children with ulcerative colitis, and 35 children with Crohn disease. Sexually mature fully grown adolescents from all three patient groups had mean pColl-I-C concentrations (12.0 +/- 0.8 micrograms/dl) similar to those previously reported for adults (5 to 17 micrograms/dl). Children with functional bowel disease and normal growth had significantly higher concentrations (32.8 +/- 1.7 micrograms/dl) (P less than 0.001) than did the fully grown adolescents. In patients with inflammatory bowel disease a significant relationship between growth velocity and pColl-I-C concentrations was noted (P less than .001). Lower pColl-I-C concentrations were found in patients receiving daily prednisone therapy compared with those receiving alternate-day therapy (P less than 0.01) or those not taking the drug (P less than 0.01). These data suggest that pColl-I-C concentrations reflect growth activity in children. Repeated determinations may allow rapid assessment of the effects of various therapeutic modalities on growth in children with inflammatory bowel disease. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
